-+ 0.00%
-+ 0.00%
-+ 0.00%

Kalaris Therapeutics Appoints Liisa Bayko CFO

Benzinga·07/20/2026 12:03:27
語音播報

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Liisa Bayko, MBA, as Chief Financial Officer.